Rev Esp Quimioter 2017, 30(4):285-292

Pleural effusion due to Parvimonas micra. A case report and a literature review of 30 cases

FERNANDO COBO, JAVIER RODRÍGUEZ-GRANGER, ANTONIO SAMPEDRO, LUIS ALIAGA-MARTÍNEZ, JOSÉ MARÍA NAVARRO-MARÍ

The clinical and microbiological characteristics of infections caused by Parvimonas micra is described, including 30 cases in the literature and a new case handled at the present centre. Out of the 31 patients, 18 were male; mean age at diagnosis was 65.1 ± 13.0 years. Infection site was the vertebral spine in 14 patients and joints and heart valves in 5 each one; pain was present in all patients with articular localization and in almost all patients with vertebral involvement. The diagnosis was obtained from fluid aspirate or drainage in 13 cases and blood cultures in 11. In 8 cases, molecular techniques were also applied. The most frequently used antimicrobials were clindamycin, penicillin, amoxicillin and ceftriaxone. The outcome was positive with the medical treatment in 28 patients. P. micra infections are uncommon and requires a high index of suspicion.

Rev Esp Quimioter 2017; 30(4):285-292 [pdf]

Rev Esp Quimioter 2017, 30(4):280-284

A descriptive study of Hafnia alvei isolated from stool samples: an approach to its clinical assessment

MÓNICA DE FRUTOS, EVA LÓPEZ, ROSA ARAGÓN, LUIS LÓPEZ-URRUTIA, CARMEN RAMOS, MARTA DOMÍNGUEZ-GIL, LOURDES VIÑUELA, SONSOLES GARCINUÑO, JOSÉ MARÍA EIROS

Introduction. The importance in human diarrhoeal disease of Hafnia alvei is unclear. The objective of the study was to describe the population which was isolated H. alvei in stool cultures and the therapeutic management of these cases in our Health Area.
Material and methods. A descriptive retrospective study was carried out in 2014 and 2015. Epidemiological, clinical, treatment and evolution variables were collected in the computerized clinical history.
Result. A collection of 7,290 stool specimens were processed, 3,321 in 2014 and 3,969 in 2015, of which 58 (1.7%) and 53 (1.3%) were positive forH. alvei, respectively. A 60.4% of samples were isolated in women. The mean age was 38.68 years. A 68.5% of samples were from primary care. In 71.2% there was related clinic, diarrhoea in 57.7%. In 75.7% of the cases there was not associated underlying disease. A 43.2% of the cases received treatment. A 66.7% of treated patients came from Primary Care. The mean duration of treatment was 8 days. The evolution was favourable in 85.4% of the cases treated. All strains were susceptible to ciprofloxacin and trimethoprim/sulfamethoxazole.
Conclusions. More evidence is needed to support H. alvei as a cause of gastroenteritis.

Rev Esp Quimioter 2017; 30(4):280-284 [pdf]

Rev Esp Quimioter 2017, 30(4):264-268

Decolonization for Staphylococcus aureus carriers in arthroplasty surgery after hip fracture

JOSÉ Mª BARBERO, JUAN ROMANYK, ALFONSO VALLÉS, MIGUEL ÁNGEL PLASENCIA, EDUARDO MONTERO, JOAQUÍN LÓPEZ

Introduction. Staphylococcus aureus is the main causative agent of joint prosthesis infections. The decolonization of the carriers is effective in the prevention of the infections of the elective arthroplasties. The aim of this study is to evaluate if it is also in arthroplasties after hip fracture.
Methods. Study in patients with hip fracture who underwent joint prosthesis from January 2011 to December 2015 with a protocol of S. aureusdetection-decolonization with intranasal mupirocin and chlorhexidine baths. Patients between January 2009 and December 2010 were the comparison group.
Results. In the intervention period, the study of colonization of S. aureus was performed in 307 patients, of whom 87 were positive (28.3%). The study period was completed by 267 patients, of whom two developed S. aureus infection, compared to six of 138 in the control group (0.7% vs 4.3%, RR 0.1, p = 0.03).
Conclusion. In our study, S. aureus decolonization in patients with hip fracture decreased the incidence of joint prosthesis infection by this microorganism.

Rev Esp Quimioter 2017; 30(4):264-268  [pdf]

Rev Esp Quimioter 2017, 30(4):276-279

Outpatient parenteral antimicrobial therapy for infective endocarditis in patients over 80 years

XABIER KORTAJARENA, MIGUEL ÁNGEL GOENAGA, MAIALEN IBARGUREN, HARKAITZ AZKUNE, MARIA JESUS BUSTINDUY, ANA FUERTES, OIHANA IBARGUREN, MUSKILDA GOYENECHE, REBECA GARCIA, GAMEGI GROUP  HOSPITAL UNIVERSITARIO DONOSTIA

Introduction. The incidence of infective endocarditis is progressively increasing, especially in elderly patients. Outpatient parenteral antibiotic therapy (OPAT) is being an excellent alternative for treatment, but advanced age is one of the relative contraindications. The aim of this study is to compare the characteristics and prognosis of patients less or more than 80 years, treated with OPAT.
Material and methods. One hundred and ninety four pa-tients were included between 1996 and 2015, 31 of them older than 80 years.
Results. The most frequently affected valve is the aortic one, mainly native valves. Most used antibiotics are ceftriaxone, ampicillin, cloxacillin and daptomycin. Differences in surgery (39.9% vs 9.7%, p=0.001) and use of infusion pump (55.2% vs 35.5%; p= 0.044) were observed, under 80 years and older respectively. No differences in readmissions and mortality were observed.
Conclusions. OPAT could be considered an effective alternative for appropriately-selected elderly patients with infective endocarditis.

Rev Esp Quimioter 2017; 30(4):276-279  [pdf]

Rev Esp Quimioter 2017, 30(4):269-275

Impact of 13-valent pneumococal conjugate polysaccharide vaccination on exacerbations rate of COPD patients with moderate to severe obstruction

JUAN MARCO FIGUEIRA-GONÇALVES, NATALIA BETHENCOURT-MARTÍN, LINA INMACULADA PÉREZ-MÉNDEZ, DAVID DÍAZ-PÉREZ, CRISTINA GUZMÁN-SÁENZ, PEDRO VIÑA-MANRIQUE, ARTURO JOSÉ PEDRERO-GARCÍA

Introduction. One of the major microorganisms described as the cause of exacerbations of chronic obstructive pulmonary disease (COPD) is Streptococcus pneumoniae. The aim of this study is to evaluate the impact of 13-valent pneumococcal conjugate polysaccharide vaccine (PCV13) in COPD patients with regard to the development of exacerbations and the possible differential effect according to the patient’s phenotype.
Material and methods. Prospective observational study of patients with COPD and FEV1 ? 65% and 18-month follow-up. Main variables: vaccination status with PCV13, phenotype “exacerbator” or “non-exacerbator”, number of exacerbations, hospitalization and deaths. A descriptive statistical analysis was performed according to the nature of the variable and an inferential analysis with CI95%, bivariate contrasts, and multivariate analysis. Significance level 5%. The statistical packages EPIDAT 3.0 and SPSS version 21.0 were used.
Results. 121 patients were included. Twenty-four percent were labeled as phenotype exacerbator. 36% were vaccinated with PCV13. During follow-up, 68% of patients had at least one exacerbation and 27% required hospitalization. We observed similarity (p> 0.05) in the number of exacerbations and deaths; however, the percentage of hospitalization in the vaccinated was 18%, compared to 32% in the non-vaccinated group. In the multivariate adjustment (controlling for the phenotype), an adjusted OR of 2.77 risk of hospitalization was observed in the non-vaccinated group (p = 0.044).
Conclusions. Non-vaccination with PCV13 almost triples the risk of hospitalization in patients with COPD.

Rev Esp Quimioter 2017; 30(4):269-275  [texto completo] [full-text ENGLISH]

Rev Esp Quimioter 2017, 30(4):257-263

Impact of a stewardship program on bacteraemia in adult inpatients

ESPERANZA MERINO, ELENA CARO, JOSÉ M. RAMOS, VICENTE BOIX, ADELINA GIMENO, JUAN CARLOS RODRÍGUEZ, GERÓNIMA RIERA, PATRICIO MÁS-SERRANO, JOSÉ SANCHÉZ-PAYA, SERGIO REUS, DIEGO TORRÚS, JOAQUÍN PORTILLA

Background. Bloodstream infections (BSIs) are associated with considerable morbidity and mortality among inpatients. The aim of this study was to evaluate the impact of a stewardship program on clinical and antimicrobial therapy-related outcomes in patients with bacteraemia.
Methods. Single-centre, before-and-after quasi-experimental study in adult inpatients. Over 1 January 2013 to 31 June 2013 all patients aged 18 years or older with a bacteraemia (interven-tion group, N=200) were compared to a historical cohort (1 Janu-ary 2012 to 31 December 2012) (control group, N=200).
Results. Following blood culture results and adjusting for potential confounders, the stewardship program was associated with more changes to antibiotic regimens (adjusted odds ratio [ORa]: 4.6, 95% CI 2.9, 7.4), more adjustments to antimicrobial therapy (ORa: 2.4, 95% CI 1.5, 3.8), and better source control in the first five days (ORa 1.6, 95% CI: 1.0, 2.7). In the subgroup that initially received inappropriate empiric treatment (n=138), the intervention was associated with more antibiotic changes (OR: 3.9, 95% CI: 1.8, 8.5) and a better choice of definitive antimicrobial therapy (OR 2.3 95% CI: 1.2, 4.6). There were also more antibiotic changes in the subgroups with both Gram-negative (OR: 2.8, 95% CI: 1.6, 4.9; n=217) and Gram-positive (OR: 4.6, 95% CI: 1.8, 9.9; n=135) bacteraemia among those receiving the intervention, while the Gram-positive subgroup also received more appropriate definitive antimicrobial therapy (OR: 3.9, 95% CI: 1.8, 8.8).
Conclusion. The stewardship program improved treatment of patients with bacteraemia and appropriateness of therapy.

Rev Esp Quimioter 2017; 30(4):257-263 [pdf]

Rev Esp Quimioter 2017, 30(4):293-296

 

Post-exposure prophylaxis against HIV, do we use our resources appropriately?                     

ROSA ESCUDERO-SÁNCHEZ, CHRISTIAN J. KURT MEIER-DE-TABOADA, EMMA BARTOLOME-GARCÍA, PATRICIA M. RODRÍGUEZ-DE-BETHENCOURT-SANJUAN, JUAN EMILIO LOSA-GARCÍA

Introduction. Post-exposure prophylaxis (PEP) against human immunodeficiency virus can be occupational, non-occupational or vertical transmission. The aim of our study was to analyse the indication and treatment carried out in a hospital.
Methods. Retrospective observational study that included all patients who received PEP between 2006 and 2014. The project was approved by the Committee for Ethics in Clinical Research.
Results. We evaluated 54 PEP, which were started at 11.8 hours’ average. The antiretroviral drugs were adequately chosen, but the duration pattern did not adjusted to the recommendations published at that time. Tolerance was good, being gastrointestinal symptoms the most frequent adverse effects; only once was necessary to replace the pattern. There were usual losses during follow up, reaching in some subgroups 50%.
Conclusion. Indication and choice of drugs were adequate in the three kinds of contact risks, but monitoring should improve.

Rev Esp Quimioter 2017; 30(4):293-296  [pdf]

Rev Esp Quimioter 2017, 30(5): 305-311

Microbiome and next generation sequencing

AVELINA SUÁREZ MOYA

The human microbiome is an internal ecosystem that refers to the community of microorganisms that populate the human body. These microorganisms are essential to support his health, because the interaction between the host immune system and microorganisms, provide the host with protection against pathogens, and contributes to the preservation of health.
Bacteriological culture has been the basis for traditional microbiology; however, most of the bacterial forms observed in nature cannot be isolated with laboratory culture methods. At present, metagenomic applies a suite of genomic technologies, where the microorganisms are identified by their genomic fingerprint.
The 16S rRNA subunit is considered as the universal target for bacterial identification from DNA with the aid of sequencing. Sanger sequencing technology had a great impact on the first generation sequencing due to its simplicity and precision. Platforms high-throughput known as second generation secuencing technologies are capable to generate hundreds of thousands of sequence reactions in a faster and economic way. However, thanks to the third generation sequencing the greatest advances in nanotechnology have been made.
Using the reference gene, the massive sequencing techniques and bioinformatics tools used for the data processing, there has been an important development of the human microbiome, achieving an unprecedented detail level on the taxonomy and microbial function. This has meant an authentic revolution not only in their knowledge but also in their involvement in the health or illness of the human being.

Rev Esp Quimioter 2017; 30(5): 305-311 [Texto completo – PDF]

Rev Esp Quimioter 2017, 30(5): 341-349

Assessment of adherence to antibiotic treatment in Primary Care by determining levels of the drug using a liquid chromatography technique

PAOLA NAVARRO-GÓMEZ, ANTONIO SORLÓZANO-PUERTO, MARÍA DEL MAR OLMO-NAVAS, PABLO NIETO-GUINDO, RAMÓN DUEÑAS-ALCALÁ, JOSÉ GUTIÉRREZ-FERNÁNDEZ, ROBERTO ROMERO-GONZÁLEZ, MANUEL ÁNGEL RODRIGUEZ-MARESCA

Introduction. The lack of adherence to antibiotic treatments is a matter of special interest, which has important clinical implications, as it is associated with therapeutic failure and increased bacterial resistance causing a high sani-tary cost. The objective of our study was to assess the degree of adherence to prescribed antibiotic treatment in outpatients through the detection of these in blood, urine or sputum.
Material and methods. Concentrations of antibiotics prescribed in 39 patients (34 with clinical suspicion of urinary tract infection and 5 with clinical suspicion of low respiratory tract infection) treated in Primary Care consultations of the Sanitary District of Almería (Spain) were determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry.
Results. A 48.7% of the patients did not comply correctly with the indicated treatment due to the complete or partial omission in taking the prescribed antibiotics. This lack of adherence was independent of the age and sex of the patients, the number of daily doses of the antibiotic, and whether or not they were receiving another medication.
Conclusions. Precise analytical techniques such as liquid chromatography can be useful to detect inadequate or incomplete treatments as well as the degree of adherence of outpatients. Thus, adequate measures could be established that affect the control of therapeutic compliance.

Rev Esp Quimioter 2017; 30(5): 341-349 [Texto completo – PDF]

Rev Esp Quimioter 2017, 30(5): 319-326

Adverse events related to medication in hospitals from the Valencian Community. EPIDEA Study 2005-2013

JUAN BAUTISTA MOLLAR-MASERES, JESUS MARÍA ARANAZ-ANDRÉS, JOSÉ MARÍA MARTIN-MORENO, JUAN JOSÉ MIRALLES-BUENO, JUANA REQUENA-PUCHE, HÉCTOR ROLANDO MARTÍNEZ-MOREL, MARÍA MERCEDES LUJÁN-TOLOSA

Introduction. To determine the prevalence of Adverse Events related to Medication (AEM) in hospitals of the Valencian Community in the 2005-2013 study period, and to describe the associated risk factors and their impact.
Material and methods. This study is based on data and methodology of the Study of Prevalence of Adverse Events in hospitals (EPIDEA), since its inception in 2005 until 2013. AEM produced in each year were analyzed.
Results. We identified 344 AEM that occurred in 337 patients, among 35,103 patients studied, giving a prevalence of patients with AEM of 0.96% (IC95% 0.89-1.07). The most prevalent intrinsic risk factors for AEM were hypertension, diabetes and cancer. The most prevalent extrinsic risk factors were peripheral venous catheter, urinary catheter and central venous catheter. Therapeutic groups most frequently involved were systemic antibiotics, cardiovascular drugs and antineoplastics.  The 61.17% of AEM was classified as moderate, followed by 27.18% as mild and 11.65% as severe. The 33.99% of EAM caused increase of the patient’s stay and 39.90% of EAM caused the re-entry of patient. The 58.5% of AEM were avoidable. Mild AEM were avoidable in 46.3%, moderate AEM were avoidable in 60.3% and severe AEM were in 75% (p = 0.013).
Conclusions. The prevalence of patients with AEM in hospitals of the Community of Valencia for the period 2005- 2013 was 0.96%. More than half of AEM were preventable, and preventability increases significantly with the severity of the event.

Rev Esp Quimioter 2017; 30(5): 319-326 [Texto completo – PDF]